InnovAge Announces Financial Results for the Fiscal Year and Fourth Quarter Ended June 30, 2021

September 21, 2021

DENVER, Sept. 21, 2021 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (the “Company” or “InnovAge”) (Nasdaq: INNV), a market leading healthcare delivery platform for high-cost, dual-eligible seniors, announced financial results for its fiscal fourth quarter and full year ended June 30, 2021.

“The InnovAge team is excited to deliver strong fourth quarter financial results to end the year with approximately 6,850 participants, an increase of 7.4% year-over-year,” said Maureen Hewitt, President and Chief Executive Officer, of InnovAge. “We produced $637.8 million of total revenues, an increase of approximately 12.5% compared to fiscal year 2020. During the pandemic, we opened two new centers and we remain on track to open de novo centers in two new states in fiscal year 2023. We also expanded our leadership team with the additions of Nicole D’Amato as Chief Legal Officer and Corporate Secretary, Eimile Tansey, Chief People Officer, and Olivia Patton, Chief Compliance Officer.”

Ms. Hewitt continued, “While COVID-19 impacted our business during fiscal year 2021, our team has done an outstanding job providing high quality, value-based care to our participants. We remain committed to ensuring our participants and employees are vaccinated against COVID-19 with a vaccination rate of 86% of participants and 90% of our employees to date. Our top priority is the health of our participants and our goal is to enable our participants to have a richer, social experience through our centers, which we are enabling in the safest way possible. We believe the landscape for future growth remains robust and we are pleased with the amount of federal and state legislative activity that we have seen in 2021. This is an exciting time to be a PACE provider and we continue to execute on our multi-faceted strategy of organic growth, de novo locations in existing and new states, and acquisitions.”

Financial Results

 Three Months Ended  Year Ended
 June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2020
 in thousands, except percentages and per share amounts
Total revenues$171,616  $152,492  $637,800  $567,192 
Center-level Contribution Margin 48,033   45,456   174,080   141,304 
Net Income (Loss) 6,315   11,978   (44,740)  25,765 
Net Income (Loss) Attributable to InnovAge Holding Corp. 6,474   12,097   (43,986)  26,278 
Net income (loss) per share - diluted$0.05  $0.09  $(0.36) $0.19 
Adjusted EBITDA(1)$19,348  $22,932  $85,333  $65,909 
Adjusted EBITDA margin(1) 11.3%  15.4%  13.4%  11.7%

Fiscal Year 2021 Financial Highlights

  • Total revenue of $637.8 million in fiscal year 2021, up 12.4% compared to $567.2 million in fiscal year 2020
  • Center-level Contribution Margin of $174.1 million, up 23.2% year-over-year, and Center-level Contribution Margin as a percent of revenue of 27.3%, an increase of approximately 240 basis points year-over-year
  • Net loss attributable to InnovAge Holding Corp. of $44.0 million, or a loss of $0.36 per share, primarily due to the Apax transaction and the Company’s initial public offering on March 8, 2021
  • Net loss of $44.7 million, a decrease from net income of $25.8 million compared to fiscal year 2020
  • Adjusted EBITDA(1) of $85.3 million, an increase of 29.5% year-over-year compared to $65.9 million in fiscal year 2020
  • Census of approximately 6,850, an increase of 7.4% year-over-year; member months of approximately 79,430, an increase of 6.1% year-over-year; and ended the fiscal year with 18 centers in five states
  • Ended the fiscal year with $201.5 million in cash and cash equivalents and $84.6 million in debt on the balance sheet, representing debt under the Company’s senior secured term loan, convertible term loan and capital leases

Fiscal Fourth Quarter 2021 Financial Highlights

  • Total revenue of $171.6 million for the fiscal fourth quarter of 2021, up 12.5% compared to $152.5 million compared to the fourth quarter of 2020
  • Center-level Contribution Margin of $48.0 million, an increase of 5.7% year-over-year, and Center-level Contribution Margin as a percent of revenue of 28.0%
  • Net income attributable to InnovAge Holding Corp. of $6.5 million, or $0.05 per share compared to $12.1 million, or $0.09 per share in the fourth quarter of 2020
  • Net income of $6.3 million compared to net income of $12.0 million for the fourth quarter of 2020. The decrease was primarily the result of increased general and administrative expense and sales and marketing expenses, partially offset by lower interest expense.
  • Adjusted EBITDA(1) of $19.3 million, compared to $22.9 million in the fourth quarter of 2020

Additional Highlights

  • On track to open three de novo centers in two new states in fiscal year 2023 and two additional de novo centers within the next 24 months
  • Re-opened centers in Pennsylvania and Virginia based on loosening state restrictions and COVID-19 infection and vaccination rates resulting in all 18 centers receiving participants in the fourth quarter
  • Made an equity investment in telehealth platform Jetdoc for the development of a purpose-built virtual care and remote patient monitoring platform for our participants and caregivers
  • Achieved goal of having 90% of employees vaccinated for COVID-19, 96% of employees have received at least one dose, and 86% of participants are currently vaccinated
  • Performed more than 110,000 telehealth visits from the start of the pandemic in March 2020 through quarter end
  • Recently, three centers in Pennsylvania, four centers in Virginia and the New Mexico PACE center were recognized as Patient-Centered Medical Homes by the National Committee for Quality Assurance
  • InnovAge is a Great Place to Work-Certified™ company for the fourth consecutive year and the Company has continued to expand its strong leadership team with the addition of Nicole D’Amato as Chief Legal Officer and Corporate Secretary, Eimile Tansey, Chief People Officer, and Olivia Patton, Chief Compliance Officer

Full Fiscal Year 2022 Financial Guidance

  Low High
  dollars in thousands
Census  7,500  7,750
Member Months  86,500  87,800
Total revenues $712 $725
Adjusted EBITDA(1) $60 $72

(1) Adjusted EBITDA is a non-GAAP measure. See “Note Regarding Use of Non-GAAP Financial Measures” and “Reconciliation of GAAP and Non-GAAP Measures” for a definition of Adjusted EBITDA and a reconciliation to net income (loss), the most closely comparable GAAP measure. The Company is unable to provide guidance for net income (loss) or a reconciliation of the Company’s Adjusted EBITDA guidance because it cannot provide a meaningful or accurate calculation or estimation of certain reconciling items without unreasonable effort. The Company’s inability to do so is due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including variations in effective tax rate, expenses to be incurred for acquisition activities and other one-time or exceptional items.

Conference Call

The Company will host a conference call this afternoon at 5:00 PM Eastern Time, which can be accessed by dialing +1 (833) 398-1024 for U.S. participants, or +1 (914) 987-7722 for international participants and referencing conference ID 3506946; or via a live audio webcast that will be available online at A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 12 months.

About InnovAge

InnovAge is a market leader in managing the care of high-cost, dual-eligible seniors. Our mission is to enable seniors to age independently in their own homes for as long as possible. Our patient-centered care model meaningfully improves the quality of care our participants receive, while reducing over-utilization of high-cost care settings. InnovAge is at the forefront of value based senior healthcare and directly contracts with government payors, such as Medicare and Medicaid, to manage the totality of a participant’s medical care. InnovAge believes its healthcare model is one in which all constituencies — participants, their families, providers and government payors— “win.” As of June 30, 2021, InnovAge serves approximately 6,850 participants across 18 centers in five states.

Investor Contact:

Ryan Kubota

Forward-Looking Statements - Safe Harbor

This press release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “believe,” “project,” “estimate,” “expect,” “may,” “should,” “will” and similar references to future periods. Forward-looking statements may be identified by the fact that they do not relate strictly to historical or current facts. Examples of forward-looking statements include, among others, statements we may make regarding our expectations to increase the number of participants we serve, to grow enrollment and capacity within existing centers, to build de novo centers, to expand into new geographies, to execute on tuck-in acquisitions, to recruit new participants and directly contract with government payors, quarterly or annual guidance, financial outlook, including future revenues and future earnings, expectation regarding legal proceedings or ongoing audits, reimbursement and regulatory developments, market developments, new products and growth strategies, integration activities and the effects of any of the foregoing on our future results of operations or financial conditions.

Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on currently available information and our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. You should not place undue reliance on our forward-looking statements. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) the risk that the cost of providing services will exceed our compensation under PACE; (ii) the dependence of our revenues upon a limited number of government payors, particularly Medicare and Medicaid; (iii) the effects of rules governing the Medicare, Medicaid or PACE programs; (iv) reductions in PACE reimbursement rates or changes in the rules governing PACE programs; (v) the risk that our submissions to government payors may contain inaccurate or unsupportable information regarding risk adjustment scores of participants, which could cause us to overstate or understate our revenue and subjecting us to payment obligations and penalties; (vi) the impact on our business of non-renewal or termination of capitation agreements with government payors; (vii) the potential adverse impact of inspections, reviews, audits, investigations, legal proceedings, enforcement actions and litigation; (viii) the impact of state and federal efforts to reduce healthcare spending; (ix) the effects of a pandemic, epidemic or outbreak of an infectious disease, including the ongoing outbreak of the COVID-19 pandemic; (x) the effect of our relatively limited operating history as a for-profit company on investors’ ability to evaluate our current business and future prospects; (xi) the viability of our growth strategy and our ability to realize expected results; and (xii) our existing indebtedness and access to capital markets. For a detailed discussion of the risks and uncertainties that could affect our actual results, please refer to the risk factors identified in our SEC reports, including, but not limited to our Prospectus, dated March 3, 2021 in connection with our IPO, our most recent Quarterly Report on Form 10-Q and our upcoming Annual Report on Form 10-K, as filed with the SEC.

Any forward-looking statement made by the Company in this press release is based only on information currently available to us and speaks only as of the date on which it is made. Except as required by law, we undertake no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Note Regarding Use of Non-GAAP Financial Measures

In addition to reporting financial information in accordance with generally accepted accounting principles (“GAAP”), the Company is also reporting Adjusted EBITDA and Adjusted EBITDA margin, which are non-GAAP financial measures. Adjusted EBITDA and Adjusted EBITDA margin are supplemental measures of operating performance monitored by management that are not defined under GAAP and that do not represent, and should not be considered as, an alternative to net income (loss) and net income (loss) margin, respectively, as determined by GAAP. We believe that Adjusted EBITDA and Adjusted EBITDA margin are appropriate measures of operating performance because the metrics eliminate the impact of revenue and expenses that do not relate to our ongoing business performance, allowing us to more effectively evaluate our core operating performance and trends from period to period. We believe that Adjusted EBITDA and Adjusted EBITDA margin help investors and analysts in comparing our results across reporting periods on a consistent basis by excluding items that we do not believe are indicative of our core operating performance. These non-GAAP financial measures have limitations as analytical tools and should not be considered in isolation from, or as a substitute for, the analysis of other GAAP financial measures, including net income (loss) and net income (loss) margin. In evaluating Adjusted EBITDA, you should be aware that in the future we may incur expenses that are the same as or similar to some of the adjustments in this presentation. Our presentation of Adjusted EBITDA should not be construed to imply that our future results will be unaffected by the types of items excluded from the calculation of Adjusted EBITDA. Our use of the term Adjusted EBITDA varies from others in our industry. We define Adjusted EBITDA as net income (loss) adjusted for interest expense, depreciation and amortization, and provision for income tax as well as addbacks for non-recurring expenses or exceptional items, including charges relating to management equity compensation, final determination of rates, M&A transaction and integration, business optimization, electronic medical record (EMR) transition, special employee bonuses, gain on consolidation of equity investee, financing-related fees and contingent consideration. Adjusted EBITDA margin is Adjusted EBITDA expressed as a percentage of our total revenue less any exceptional, one-time revenue items. For a full reconciliation of Adjusted EBITDA to the most closely comparable GAAP financial measure, please see the attachment to this earnings release.

Schedule 1
     June 30,     June 30, 
  2021 2020
  in thousands
Current Assets      
Cash and cash equivalents $201,466 $112,904 
Restricted cash  2,234  1,661 
Accounts receivable, net of allowance ($4,350 – June 30, 2021 and $6,384 – June 30, 2020)  32,582  46,312 
Prepaid expenses  9,249  4,311 
Income tax receivable  5,401  1,743 
Total current assets  250,932  166,931 
Noncurrent Assets      
Property and equipment, net  142,715  102,494 
Investments  2,645  2,645 
Deposits and other  3,877  3,003 
Equity method investments  848  13,245 
Goodwill  124,217  116,139 
Other intangible assets, net  6,518  5,177 
Total noncurrent assets  280,820  242,703 
Total assets $531,752 $409,634 
Liabilities and Stockholders' Equity      
Current Liabilities      
Accounts payable and accrued expenses $32,361 $28,875 
Reported and estimated claims  33,234  30,291 
Due to Medicaid and Medicare  7,101  12,244 
Current portion of long-term debt  3,790  1,938 
Current portion of capital lease obligations  2,079  1,496 
Contingent consideration    1,789 
Total current liabilities  78,565  76,633 
Noncurrent Liabilities      
Deferred tax liability, net  15,700  9,282 
Capital lease obligations  5,190  4,091 
Other noncurrent liabilities  2,758  1,446 
Long-term debt, net of debt issuance costs  71,574  210,432 
Total liabilities  173,787  301,884 
Commitments and Contingencies (See Note 12)      
Stockholders’ Equity      
Common stock, $0.001 par value; 500,000,000 authorized as of June 30, 2021 and 2020; 135,516,513 and 132,718,461 issued shares as of June 30, 2021 and June 30, 2020, respectively  136  133 
Additional paid-in capital  323,760  36,338 
Retained earnings  11,250  64,737 
Less: Treasury stock; 0 and 102,030 shares of common stock at $0.0 and $1.89 per share as of June 30, 2021 and June 30, 2020, respectively    (193)
Total InnovAge Holding Corp.  335,146  101,015 
Noncontrolling interests  22,819  6,735 
Total stockholders’ equity  357,965  107,750 
Total liabilities and stockholders’ equity $531,752 $409,634 

Schedule 2
 Three Months Ended  Year Ended
 June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2020
 in thousands, except per share amounts
Capitation revenue$171,028  $152,110  $635,322  $564,834 
Other service revenue 588   382   2,478   2,358 
Total revenues 171,616   152,492   637,800   567,192 
External provider costs 85,102   68,445   309,317   272,832 
Cost of care, excluding depreciation and amortization 38,481   38,591   154,403   153,056 
Center-level Contribution Margin 48,033   45,456   174,080   141,304 
Sales and marketing 7,901   4,596   22,236   19,001 
Corporate, general and administrative 26,432   16,064   132,333   58,481 
Depreciation and amortization 3,032   2,981   12,294   11,291 
Equity loss    475   1,343   678 
Other operating expense    1,170   18,211   920 
Total expenses 160,948   132,322   650,137   516,259 
Operating Income (Loss) 10,668   20,170   (12,337)  50,933 
Other Income (Expense)           
Interest expense, net 274   (3,332)  (16,787)  (14,619)
Loss on extinguishment of debt       (14,479)   
Gain on equity method investment       10,871    
Other expense (15)  54   (2,237)  (681)
Total other expense 259   (3,278)  (22,632)  (15,300)
Income (Loss) Before Income Taxes 10,927   16,892   (34,969)  35,633 
Provision for Income Taxes 4,612   4,914   9,771   9,868 
Net Income (Loss) 6,315   11,978   (44,740)  25,765 
Less: net loss attributable to noncontrolling interests (159)  (119)  (754)  (513)
Net Income (Loss) Attributable to InnovAge Holding Corp.$6,474  $12,097  $(43,986) $26,278 
Weighted-average number of common shares outstanding - basic 135,516,513   132,616,431   123,618,702   132,616,431 
Weighted-average number of common shares outstanding - diluted 135,517,753   135,233,630   123,618,702   135,233,630 
Net income (loss) per share - basic$0.05  $0.09  $(0.36) $0.20 
Net income (loss) per share - diluted$0.05  $0.09  $(0.36) $0.19 

Schedule 3
  Year Ended June 30,
  2021 2020
  in thousands
Operating Activities      
Net income (loss) $(44,740) $25,765 
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities      
Loss on disposal of assets  18   1,039 
Provision for uncollectible accounts  8,637   6,204 
Depreciation and amortization  12,294   11,291 
Gain on equity method investment  (10,871)   
Loss on extinguishment of long-term debt  14,479    
Amortization of deferred financing costs  1,056   550 
Stock-based compensation  1,664   543 
Deferred income taxes  6,418   3,173 
Loss in equity of nonconsolidated entities  1,343   678 
Change in fair value of warrants  2,264    
Change in fair value of contingent consideration     920 
Changes in operating assets and liabilities, net of acquisitions      
Accounts receivable, net  5,879   (1,202)
Prepaid expenses  (4,987)  (1,062)
Income tax receivable  (3,658)  1,952 
Deposits and other  (874)  1,063 
Accounts payable and accrued expenses  6,137   (1,013)
Reported and estimated claims  2,613   2,045 
Due to Medicaid and Medicare  (5,220)  (8,120)
Deferred revenue     2 
Net cash provided by (used in) operating activities  (7,548)  43,828 
Investing Activities      
Purchases of property and equipment  (17,541)  (11,844)
Proceeds from sales of property and equipment     169 
Proceeds from net working capital settlements     1,129 
Purchase of long term investment     (1,145)
Purchase of intangible assets  (2,000)   
Net cash used in investing activities $(19,541) $(11,691)
Financing Activities      
Distributions to owners $(9,500) $ 
Capital contributions  20,000    
Payments on capital lease obligations  (1,788)  (1,834)
Proceeds from long-term debt  375,000   25,000 
Principal payments on long-term debt  (512,660)  (1,934)
Payment of financing costs and debt premiums  (14,896)   
Proceeds from initial public offering of common stock  370,468    
Treasury stock purchases  (77,603)   
Payments under acquisition agreements  (3,622)   
Payments related to option cancellation  (29,175)   
Net cash provided by financing activities  116,224   21,232 
Supplemental Cash Flows Information      
Interest paid $18,030  $11,551 
Income taxes paid $7,048  $4,745 
Property and equipment included in accounts payable $1,327  $1,348 
Property and equipment purchased under capital leases $3,493  $1,399 

Schedule 4
   Three Months Ended  Year Ended
   June 30, 2021 June 30, 2020 June 30, 2021 June 30, 2020
   in thousands
Net income (loss)$6,315  $11,978  $(44,740) $25,765 
Interest expense, net (274)  3,332   16,787   14,619 
Depreciation and amortization 3,032   2,981   12,294   11,291 
Provision for income tax 4,612   4,914   9,771   9,868 
Stock-based compensation 562   136   1,664   543 
Rate determination(a)    (3,173)  (2,158)  (3,372)
M&A diligence, transaction and integration(b) 4,273   177   67,606   2,718 
Business optimization(c) 702   549   1,829   1,171 
EMR implementation(d) 126   317   461   1,078 
Special employee bonus(e)    551      1,278 
Gain on consolidation of equity investee(f)       (10,871)   
Financing-related(g)       14,479   30 
Contingent consideration(h)    1,170   18,211   920 
Adjusted EBITDA$19,348  $22,932  $85,333  $65,909 
(a) For the year ended June 30, 2021, this reflects the CMS settlement payment of approximately $2.2 million related to end-stage renal disease beneficiaries for calendar years 2010 through 2020. For the three and twelve months ended June 30, 2020, this reflects the final determination of certain rates for capitation payments from the State of California, all of which we consider non-recurring.
(b) For the year ended June 30, 2021, this primarily represents (i) $45.4 million related to the cancellation of options and the redemption of shares, including $3.2 million recognized during the fourth quarter of fiscal year 2021, and (ii) $13.1 million of transaction fees and expenses recognized in connection with the July 27, 2020 transaction between us, an affiliate of Apax Partners and our existing equity holders entering into a Securities Purchase Agreement.
(c) Reflects charges related to business optimization initiatives. Such charges relate to one-time investments in projects designed to enhance our technology systems and improve the efficiency and effectiveness of our operations.
(d) Reflects non-recurring expenses relating to the transition to a new electronic medical record vendor.
(e) Reflects non-recurring special bonuses paid to certain of our employees of the Company relating to shareholder dividend transactions that occurred in fiscal years 2018 and 2019.
(f) Reflects non-recurring expense related to the gain on consolidation of InnovAge California PACE-Sacramento, LLC.
(g) Reflects fees and expenses incurred in connection with amendments to our credit agreements.
(h) Reflects the contingent consideration fair value adjustment made during the reporting period associated with our acquisition of NewCourtland LIFE Program which closed during our fiscal year ended June 30, 2019.


Print Page
Email Alerts
RSS Feeds
Contact IR